Phase 3 registrational study, evaluating inhaled KB707 in combination with chemotherapy against chemotherapy alone in patients with advanced NSCLC
Latest Information Update: 26 Nov 2025
At a glance
- Drugs Antineoplastics (Primary) ; KB 707 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Registrational; Therapeutic Use
Most Recent Events
- 26 Nov 2025 New trial record
- 03 Nov 2025 According to the Krystal Biotech media release, the Company now expects that a single Phase 3 registrational study, evaluating inhaled KB707 in combination with chemotherapy against chemotherapy alone in patients with advanced NSCLC, would be sufficient to support potential registration of inhaled KB707 in combination with chemotherapy as a second-line treatment for NSCLC.